moneyheap
AXSM · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Axsome Therapeutics, Inc (AXSM) stock moving?
Axsome reported Q3 2026 results on Nov 2 that beat expectations: total net product revenue rose 52% year over year to $259.7M, Auvelity grew 53% to $207.6M, Sunosi reached $48.2M (including an $8.5M milestone), and Symbravo nearly doubled to $3.9M. The net loss narrowed to $12.9M from $47.2M, and management said cash is sufficient to reach cash-flow positivity and that annual revenue now exceeds a $1B run rate. Despite this, the stock fell 5.8% to $136.01 on Nov 2 after trading as low as $123.00, and analysts mostly trimmed price targets (Baird to $220, RBC to $273, UBS to $239, Mizuho to $272), while Morgan Stanley raised its target to $249. Ratings were largely held, with Outperform and Buy calls prevailing. The stock then recovered to $139.61 on Nov 3 and closed at $140.97 on Nov 10, up 5.2% on 1.29M shares, about 1.1x the recent average. It remains roughly 10% below its Oct 22 close of $156.07. Pipeline catalysts are concentrated later: the AXS-12 narcolepsy FDA decision on May 1, 2027, ENGAGE binge eating Phase 3 data in Q1 2027, and a newly started SUMMIT smoking-cessation Phase 3 trial. The main risk is that the quarter's strength has not yet translated into higher targets, and the binary regulatory and trial events lie ahead.
News behind the analysis
- Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateQ3 2026 total net product revenue rose 52% year over year to $259.7M, with Auvelity at $207.6M (+53%) and Sunosi at $48.2M (+47%). The company said cash is sufficient to fund operations through cash-flow positivity.
- Axsome CEO: Revenue Passes $1B Annual Run RateCEO Herriot Tabuteau said quarterly revenue now implies an annual run rate above $1 billion. He pointed to continued new patient starts for Auvelity in Alzheimer's disease agitation.
- Axsome Q3 Net Loss $12.9M vs $47.2M Y/YThe third-quarter net loss narrowed sharply from $47.2M a year earlier to $12.9M. Reported EPS of a $0.25 loss was ahead of analyst expectations.
- Axsome AXS-12 Narcolepsy Decision Date Set For 1 May 2027The FDA decision date for AXS-12 in narcolepsy is set for May 1, 2027. This is a key regulatory milestone for the pipeline.
- Axsome Sees Phase 3 ENGAGE Binge Eating Disorder Data In Q1 2027The company expects Phase 3 ENGAGE binge eating disorder data in Q1 2027. The readout is a pipeline catalyst beyond the current quarter.
- Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220Baird kept its Outperform rating but cut its price target from $246 to $220 after the Q3 report.
- RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273RBC kept its Outperform rating and lowered its price target from $295 to $273 following Q3 results.
- Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249Morgan Stanley kept its Equal-Weight rating and raised its price target to $249 after Q3 results.
- UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239UBS kept its Buy rating and lowered its price target to $239 following the third-quarter report.
- Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272Mizuho kept its Outperform rating and lowered its price target to $272. Most post-earnings target changes were trims, even though the quarter beat expectations.
About Axsome Therapeutics, Inc
Axsome Therapeutics is a New York-based biopharmaceutical company that develops and sells medicines for brain and nervous-system disorders such as depression, Alzheimer's disease agitation, narcolepsy and migraine. It stands out as a fast-growing commercial-stage biotech: its quarterly revenue topped a roughly $1 billion annual run rate in late 2026, and it has a pipeline of about 10 programs.
How it makes money
Almost all revenue comes from US sales of its prescription drugs. Auvelity, used for major depressive disorder and since mid-2026 for agitation in Alzheimer's dementia, makes up about 80% of sales (about $208M of roughly $260M in Q3 2026). Sunosi, a drug for excessive daytime sleepiness, adds about 18%, and the migraine drug Symbravo is a small remainder. The company was still posting a small net loss in 2026 while it spent on research and development and its sales force.
What usually moves AXSM
- Auvelity prescription growth, including the Alzheimer's agitation launch
- FDA decisions on pipeline drugs such as AXS-12 for cataplexy
- Late-stage clinical trial results (e.g., smoking cessation, schizophrenia)
- Insurance coverage and gross-to-net pricing discounts
- Path to profitability and cash flow